Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This trial will compare the efficacy and toxicity of standard first-line chemotherapy alone
vs. standard chemotherapy plus sorafenib in patients with stage III/IV ovarian cancer
following cytoreductive surgery. Patients with residual large volume disease and/or bowel
involvement will be excluded, to minimize the risk of bowel perforation.